Placebo to Match GSK3915393 Tablet clinical trials

A Phase 2, randomized, double-blind, placebo-controlled, parallel group study (TRANSFORM) to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)

This study is testing a new medicine, GSK3915393, for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). We want to see if it helps improve breathing and is safe over 26 weeks. Some people will get the new medicine, and others a dummy pill.